Can a Patient's own stem cells reset the immune system to halt brain damage?
NCT ID NCT07757685
First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time
Summary
This trial is testing whether a transplant of a patient's own blood-forming stem cells can ease neurological damage caused by hereditary homocysteine remethylation disorders, a rare genetic condition that affects metabolism. The approach aims to reset the immune system and reduce inflammation in the brain. Researchers will monitor safety, how well the transplant works, and changes in neurological function and brain scans. The study includes adults aged 18 to 55 with confirmed diagnosis and neurological symptoms who have not responded well to standard metabolic therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Autologous hematopoietic stem cell transplantation (using the patient's own stem cells)
- What this could lead to
- If successful, this approach could offer a way to slow or reverse neurological damage in people with hereditary homocysteine remethylation disorders, potentially improving their quality of life.
- What could go wrong
- This is an early exploratory study, so safety and effectiveness are not yet proven. The procedure carries risks like infection, organ damage, and failure to collect enough stem cells.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEREDITARY HOMOCYSTEINE REMETHYLATION DISORDER are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
General Hospital of Tianjin Medical University
Tianjin, Tianjin Municipality, 300070, China
-
Institute of Hematology & Blood Diseases Hospital, China
Tianjin, Tianjin Municipality, 300020, China